论文部分内容阅读
随着对肿瘤发病机制及其生物学行为的深入研究,分子靶向治疗成为目前治疗非小细胞肺癌(non-small cell lung cancer,NSCLC)最具前景的研究领域。表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)可延长患者无进展生存期并明显提高患者生活质量,然而耐药已成为影响该类药物临床应用的最大障碍。全文就一代和三代EGFR-TKI的耐药机制与治疗策略的研究进展进行综述。
With the in-depth study on the pathogenesis of tumor and its biological behavior, molecular targeted therapy has become the most promising research field in the treatment of non-small cell lung cancer (NSCLC). Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) can prolong the progression-free survival of patients and significantly improve the quality of life of patients, however, drug resistance has become the clinical application of these drugs The biggest obstacle. The article reviews the research progress of the drug resistance mechanisms and treatment strategies of the first generation and third generation of EGFR-TKI.